Proactive Research analyst Emma Ulker discusses MaxCyte’s () new clinical and commercial licence agreement with Caribou Biosciences.
She says the agreement which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborations in cell and gene therapy.
Click here to read Emma Ulker's latest update on Maxcyte
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE